{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015693","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.177700+00:00","generated_at":"2026-06-15T20:43:13.667715+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cardiff Oncology Q1 2023: Cash $97M, first patient dosed in ONSEMBLE trial","bullets":["Cash, cash equivalents & short-term investments of $97M as of March 31, 2023; projected runway into 2025.","First patient dosed in Phase 2 ONSEMBLE trial of onvansertib for KRAS/NRAS-mutated metastatic CRC.","Appointed Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer.","Operating expenses $12.1M in Q1 2023, up from $11.1M in Q1 2022.","Net cash used in operations $8.7M in Q1 2023, compared to $10.2M in Q1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015693","json":"https://secwatch.observer/filing/0001628280-23-015693.json","markdown":"https://secwatch.observer/filing/0001628280-23-015693.md","text":"https://secwatch.observer/filing/0001628280-23-015693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023015693/0001628280-23-015693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023015693/crdf-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:43:13.667715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e0f7c2257f091d5af8446991f4ea87fe08c86d42","claim":"Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"On May 4, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023015693/0001628280-23-015693-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}